You are here

Cytokinetics

Cytokinetics initiates trial of aficamten to treat nHCM

Cytokinetics initiates trial of aficamten to treat nHCM

Clinical Trials Arena

clinical trials

non-obstructive hypertrophic cardiomyopathy

Flag link:

Unpartnered assets: on the shelf or hidden treasure?

Unpartnered assets: on the shelf or hidden treasure?

EP Vantage

Ascendis Pharma

Karuna Therapeutics

Madrigal Pharmaceuticals

Protagonist Therapeutics

Ultragenyx Pharmaceutical

Ventyx Biosciences

Flag link:

As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate

As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate

Clinical Trials Arena

clinical trials

Flag link:

Cytokinetics’ pipeline tumble continues after ALS med flops in phase 3 interim look

Cytokinetics’ pipeline tumble continues after ALS med flops in phase 3 interim look

Fierce Biotech

clinical trials

Flag link:

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv

Fierce Pharma

complete response letter

Omecamtiv Mecarbil

Flag link:

FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use

FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use

Fierce Biotech

Omecamtiv Mecarbil

Flag link:

Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug

Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug

Endpoints

Omecamtiv Mecarbil

Flag link:

Go or no go? Mirati heads to the FDA

Go or no go? Mirati heads to the FDA

EP Vantage

Mirati Therapeutics

Gilead Sciences

Coherus Biosciences

TG Therapeutics

Flag link:

FDA Review: Alnylam, Cytokinetics, Eli Lilly and More

FDA Review: Alnylam, Cytokinetics, Eli Lilly and More

BioSpace

Boston Cell Standards

Kiromic Biopharma

Transcenta Holdings

Kira Pharmaceuticals

Seneca Therapeutics

Flag link:

Cytokinetics aims to become the Vertex of cardiovascular disease

Cytokinetics aims to become the Vertex of cardiovascular disease

EP Vantage

Omecamtiv Mecarbil

cardiovascular disease

Flag link:

Cytokinetics hopes to resurrect omecamtiv

Cytokinetics hopes to resurrect omecamtiv

EP Vantage

Omecamtiv Mecarbil

Flag link:

Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect

Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect

Fierce Biotech

Omecamtiv Mecarbil

Ji Xing Pharmaceuticals

Flag link:

Biogen leads the amyotrophic lateral sclerosis hopefuls

Biogen leads the amyotrophic lateral sclerosis hopefuls

EP Vantage

Ionis Pharmaceuticals

Flag link:

Cytokinetics heart drug succeeds in mid-stage study, boosting shares

Cytokinetics heart drug succeeds in mid-stage study, boosting shares

BioPharma Dive

clinical trials

obstructive hypertrophic cardiomyopathy

Flag link:

ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

Fierce Biotech

Omecamtiv Mecarbil

Flag link:

Astellas quietly cuts Cytokinetics R&D pact as $450M-plus in biobucks goes up in smoke

Astellas quietly cuts Cytokinetics R&D pact as $450M-plus in biobucks goes up in smoke

Fierce Biotech

Flag link:

Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results

Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results

Endpoints

clinical trials

Flag link:

AHA 2020 – look out for the omecamtiv fault lines

AHA 2020 – look out for the omecamtiv fault lines

EP Vantage

Omecamtiv Mecarbil

Flag link:

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

BioPharma Dive

clinical trials

Omecamtiv Mecarbil

cardiovascular disease

Flag link:

Pages